endometrial cancer
Merck's Keytruda Added to Adjuvant Chemo Benefits Newly Diagnosed Endometrial Cancer Subpopulation
Premium
The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.
The firm recently started treating patients in a Phase I trial of its pol theta helicase inhibitor and filed an IND for its Werner helicase-targeted drug candidate.
European Commission Approves AstraZeneca's Imfinzi Regimens Based on MMR Status
Depending on MMR status, endometrial cancer patients can receive first-line therapy with Imfinzi and chemo followed by Imfinzi alone or Imfinzi with Lynparza.
CHMP Recommends AstraZeneca's Imfinzi, Lynparza for Endometrial Cancer Based on MMR Status
The committee reviewed data from the DUO-E trial to recommend approval for Imfinzi or Imfinzi-Lynparza as maintenance therapy, depending on biomarker status.
Lyell Immunopharma to Test CAR T-Cell Therapy in Variety of ROR1-Positive Cancers
After seeing promising activity in TNBC, the firm will test LYL797 in ROR1-positive ovarian and endometrial cancer, and certain blood cancers.